acute coronary syndrome Flashcards
types of ACS
NSTEMI (Non-st elevation MI)
STEMI ( ST-elevation MI)
unstable angina
describe the mechanism of action of thrombolytic therapy
dissolve blood clots by activating plasminogen, which forms a cleaved product called plasmin
tPA binds to plasminogen on surface of fibrin (at location of thrombus) - conversion of plasminogen to plasmin happens here
aka fibrinolytics/thrombolysis
strengths and weaknesses of thrombolytic therapy
major trials which prove advantage of thrombolytic therapy
benefits of aspirin therapy in patients with ischemic heart disease
aspirin helps prevent blood clots from forming in your arteries and may lower your risk for a stroke or heart attack
advantages substantially outweigh the risks
treatment of MI
aspirin tablets
thrombolytic or clot dissolving drugs such as tPA, streptokinase or urokinase
recognise common complications of MI
disturbance of rate, rhythm, conduction cardiac rupture heart failure pericarditis ventricular septal defect ventricular aneurysm ruptured papillary muscles
describe rehab following MI
customised outpatient program of exercise and education
designed to help improve health and recover from heart attack, other forms of heart disease or surgery to treat disease
start several weeks after hosp discharge
follow-up and identification of high risk patients for MI
black patients HTN hypercholesterolaemia LV hypertrophy diabetes male gender advancing age smoking obesity FH
common to see patient 3-6 weeks after discharge
non-STEMI - outpatient follow up for low risk patients and those who have undergone revascularisation - 2-6weeks
strengths and weaknesses of beta adrenoreceptor antagonists
strengths and weaknesses of CCBs
strengths and weaknesses of low dose aspirin
potential roles for BBs in prevention of MI & angina
potential roles for simvastatin in prevention of MI & angina
potential roles for ACE inhibitors in prevention of MI & angina
